SS-31 (Elamipretide): the mitochondrial-targeted peptide — 2026 evidence-based guide

Mitochondrial dysfunction is implicated in virtually every disease of aging: heart failure, neurodegeneration, sarcopenia, kidney disease, macular degeneration, metabolic syndrome. The problem has always been reaching mitochondria with therapeutic molecules. Conventional antioxidants like vitamin C and vitamin E distribute throughout the entire cell, reaching mitochondria only at trivial concentrations. Coenzyme Q10 gets closer but still faces membrane permeability barriers. For decades, the mitochondrial interior has been pharmacologically inaccessible.

SS-31 changed that equation. Designed by Hazel Szeto at Weill Cornell Medical College, this four-amino-acid peptide exploits the strong negative electrical potential across the inner mitochondrial membrane to concentrate itself over 1000-fold at precisely the location where electron transport chain dysfunction generates the oxidative damage that drives cellular aging. It is not an antioxidant in the conventional sense — it does not scavenge free radicals after they are produced. Instead, it prevents their overproduction by stabilizing the molecular architecture of the electron transport chain itself.

The science behind SS-31 is among the most elegant in the peptide field. The clinical development story has been considerably less elegant — marked by promising early data, ambitious trials, missed endpoints, and an FDA rejection that left the molecule in regulatory limbo. This guide covers both the biology and the business, because understanding where SS-31 stands in 2026 requires both.

What is SS-31?

SS-31 (Szeto-Schiller peptide 31) is a synthetic tetrapeptide with the sequence D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2. The "SS" refers to Hazel Szeto and Peter Bhatt Schiller, who first described the Szeto-Schiller peptide family in 2000 as a new class of cell-permeable, mitochondria-targeted compounds. SS-31 was the most promising candidate from this series, selected for clinical development under the names Bendavia, MTP-131, and ultimately elamipretide.

Several structural features make SS-31 remarkable. It is tiny — only four amino acids — yet it incorporates a non-natural amino acid (2',6'-dimethyltyrosine, or Dmt) and a D-form arginine that confer resistance to enzymatic degradation. The alternating cationic-aromatic motif (positively charged amino acid, then aromatic, then positive, then aromatic) allows it to cross cell membranes without a transporter and accumulate in mitochondria driven by the organelle's 180 mV membrane potential. Most drugs cannot enter mitochondria at all; SS-31 concentrates there preferentially.

Stealth BioTherapeutics (now Stealth Biotherapeutics Corp) licensed elamipretide and advanced it through clinical development for multiple indications associated with mitochondrial dysfunction. The company went public on the Nasdaq in 2019, fueled by early clinical promise, and has since navigated the challenges of developing a first-in-class mitochondrial therapeutic through the FDA regulatory process.

How does SS-31 work? Mechanism of action

SS-31's mechanism is distinct from every other "mitochondrial support" compound on the market. It does not donate electrons (like CoQ10), scavenge free radicals (like vitamin E), or provide metabolic substrates (like NAD+ precursors). It works by physically stabilizing the mitochondrial inner membrane's architecture:

• Cardiolipin binding and stabilization — SS-31 interacts with cardiolipin through electrostatic and hydrophobic interactions, stabilizing cardiolipin's conformation and protecting it from peroxidation by locally generated ROS. This preserves the "lipid platform" on which electron transport chain complexes sit
• Electron transport chain optimization — By maintaining cardiolipin integrity, SS-31 preserves the spatial organization of Complexes I, III, and IV (and their supercomplexes), ensuring efficient electron channeling. Electrons flow through the intended pathway rather than leaking to oxygen prematurely
• ROS reduction at the source — Unlike conventional antioxidants that neutralize free radicals after they form, SS-31 prevents excess ROS generation by keeping the electron transport chain operating efficiently. This is a fundamentally different and more effective approach — reducing production rather than attempting cleanup
• Cytochrome c interaction — SS-31 also modulates cytochrome c's interaction with cardiolipin, shifting cytochrome c from a peroxidase conformation (which damages cardiolipin) back to its normal electron carrier conformation. This breaks a vicious cycle where cardiolipin damage produces more cardiolipin damage
• Mitochondrial permeability transition pore (mPTP) stabilization — By maintaining inner membrane integrity, SS-31 reduces the probability of mPTP opening — a catastrophic event that triggers mitochondrial-mediated apoptosis. This contributes to cell survival under stress conditions
• ATP synthesis enhancement — The net effect of improved electron transport efficiency is greater ATP yield per unit of oxygen consumed. In aged or damaged mitochondria, SS-31 has been shown to restore ATP output toward youthful levels in both animal and ex vivo human tissue studies

The elegance of this mechanism cannot be overstated. Rather than adding an external compound to compensate for mitochondrial dysfunction, SS-31 restores the structural conditions under which mitochondria function correctly on their own. The distinction matters: it is the difference between giving a failing engine more fuel versus realigning the pistons so the existing fuel burns efficiently.

Clinical trial results: the promise and the reality

Barth syndrome — the primary indication

Barth syndrome is a rare, X-linked genetic disorder caused by mutations in the tafazzin gene, which is essential for cardiolipin synthesis and remodeling. Patients have abnormal cardiolipin composition, leading to mitochondrial dysfunction, cardiomyopathy, skeletal myopathy, neutropenia, and growth retardation. It is the quintessential cardiolipin disorder — and therefore the most mechanistically appropriate target for SS-31.

The TAZPOWER open-label trial enrolled 12 Barth syndrome patients and demonstrated meaningful improvements in the six-minute walk test (6MWT), a standard functional capacity measure. Patients gained an average of 60 meters in walking distance — clinically significant for a severely debilitated population. The improvements appeared durable over a 36-week treatment period, and patients reported subjective improvements in fatigue and daily functioning.

Based on these results and the unmet medical need (no approved therapies for Barth syndrome existed), Stealth BioTherapeutics submitted a New Drug Application to the FDA in 2022. The FDA issued a Complete Response Letter in 2023, declining to approve elamipretide and requesting additional controlled trial data. The rejection centered on the open-label design of TAZPOWER — without a placebo control group, the FDA could not attribute the functional improvements definitively to elamipretide rather than to placebo effect, natural variation, or the supportive care provided during the trial.

Heart failure — the EMBRACE trial

Heart failure with reduced ejection fraction (HFrEF) represents a massive potential market and a clear mechanistic rationale for SS-31: failing hearts are energy-starved, mitochondrial dysfunction is well-documented in cardiomyocytes, and cardiolipin abnormalities have been demonstrated in explanted failing hearts. The EMBRACE trial enrolled 71 patients with stable HFrEF and treated them with elamipretide or placebo for 4 weeks, with left ventricular end-systolic volume (LVESV) as the primary endpoint.

EMBRACE missed its primary endpoint — there was no statistically significant difference in LVESV between the elamipretide and placebo groups. The trial did show trends toward improvement in secondary endpoints (stroke volume, cardiac output) and was likely underpowered at 71 patients for the degree of change expected. Subgroup analyses suggested potential benefit in patients with more severe mitochondrial dysfunction, but post-hoc subgroup analyses are hypothesis-generating, not confirmatory.

The heart failure results illustrate a broader challenge in mitochondrial medicine: even when the mechanism is clear and the preclinical data is strong, translating to measurable clinical improvement in a complex, multifactorial disease like heart failure is extraordinarily difficult. The heart does not fail solely because of mitochondrial dysfunction — neurohormonal activation, fibrosis, volume overload, and genetic factors all contribute. Fixing one component of a multi-component problem may not produce a detectable signal at the whole-organ level.

Age-related macular degeneration (AMD)

The retinal pigment epithelium (RPE) is one of the most mitochondria-dense tissues in the body, making it a biologically rational target for SS-31. The ReCLAIM trials tested subcutaneous elamipretide in patients with non-exudative (dry) AMD. ReCLAIM-1 showed improvement in low-luminance visual acuity — a measure of retinal function under dim conditions that is sensitive to mitochondrial dysfunction in RPE cells. ReCLAIM-2, a larger Phase 2 trial, showed mixed results: some visual function endpoints improved while others did not reach significance.

AMD remains an area of active investigation for elamipretide. Dry AMD has no approved therapy (anti-VEGF injections treat only the "wet" form), creating substantial unmet need and regulatory motivation to advance novel mechanisms.

Primary mitochondrial myopathy

The MMPOWER trials tested elamipretide in patients with genetically confirmed primary mitochondrial myopathy — diseases caused by mutations in mitochondrial DNA or nuclear genes encoding mitochondrial proteins. These patients have demonstrable mitochondrial dysfunction by definition, making them perhaps the most mechanistically appropriate population. MMPOWER-3, the Phase 3 trial, did not meet its primary endpoint of improvement in the six-minute walk test, though it showed signals of benefit in patient-reported fatigue measures.

Preclinical aging data: what animal studies show

While the clinical trial results have been mixed, the preclinical data for SS-31 in aging models remains striking and consistently positive across multiple research groups and organ systems:

• Cardiac aging — SS-31 treatment in aged mice (24 months) reversed diastolic dysfunction, reduced cardiac hypertrophy, and restored mitochondrial ATP production to levels comparable to young mice (4 months) within weeks of treatment. These results from Peter Bhatt Rabinovitch's laboratory at the University of Washington were published in high-impact journals
• Skeletal muscle — Aged mice treated with SS-31 showed increased exercise tolerance, improved mitochondrial coupling efficiency, and reduced oxidative damage in skeletal muscle. Single-fiber studies demonstrated restoration of calcium handling and contractile function toward youthful levels
• Kidney aging — SS-31 reduced age-related glomerulosclerosis and tubulointerstitial fibrosis in aged mouse kidneys, with accompanying improvements in glomerular filtration rate and reduction in proteinuria. The kidney is highly mitochondria-dependent, making it an expected responder
• Brain and cognition — Short-term SS-31 treatment improved cognitive performance on spatial memory tasks in aged mice, concurrent with restoration of synaptic mitochondrial function in the hippocampus
• Insulin sensitivity — Aged mice treated with SS-31 showed improved whole-body insulin sensitivity concurrent with enhanced mitochondrial function in liver and skeletal muscle, suggesting metabolic benefits beyond specific organ protection

The consistency of these preclinical results across different organ systems, different research groups, and different aging endpoints is notable. SS-31 is not a molecule where one laboratory produced a single impressive finding — the aging biology is robust and reproducible. The challenge is that robust mouse aging data does not automatically translate to robust human clinical outcomes, as the clinical trial results have demonstrated.

What has Huberman Lab said about SS-31 and mitochondrial peptides?

Andrew Huberman has discussed mitochondrial health extensively across multiple Huberman Lab episodes, particularly in the context of aging, exercise physiology, and cellular energy production. His coverage of mitochondrial biology has been substantive, addressing electron transport chain function, the role of reactive oxygen species as both signaling molecules and damage agents, and the connection between mitochondrial dysfunction and age-related disease.

SS-31 specifically has been mentioned in longevity biology contexts rather than receiving a dedicated deep dive. Huberman has discussed the general concept of mitochondria-targeted therapeutics and has noted that compounds like SS-31 represent a pharmacologically distinct approach from conventional antioxidant supplementation. His coverage of cardiolipin biology and electron transport chain function provides helpful mechanistic context for understanding why SS-31's approach is novel.

More broadly, Huberman has devoted considerable attention to non-pharmacological mitochondrial optimization strategies: cold exposure (which upregulates mitochondrial biogenesis through PGC-1alpha activation), exercise (the most potent known stimulus for mitochondrial adaptation), and deliberate heat exposure (which activates heat shock proteins that support mitochondrial protein quality control). His consistent message — that behavioral interventions for mitochondrial health have stronger evidence bases than most supplements — aligns with the clinical evidence for SS-31: the biology is compelling, but the human outcome data is still developing.

Where Huberman's general mitochondrial content connects to SS-31: his discussions of how mitochondrial dysfunction propagates into organ-level disease (particularly cardiac, neurological, and metabolic disease) provide the scientific context for understanding why a mitochondria-targeted therapeutic like SS-31 is conceptually attractive. The gap he identifies between mechanistic understanding and clinical proof applies directly to elamipretide's development story.

SS-31 compared to other mitochondrial interventions

SS-31's mechanism is the most precisely targeted of any mitochondrial intervention — it goes directly to the inner membrane and addresses cardiolipin integrity at the molecular level. This specificity is both its greatest strength (mechanistic elegance) and a limitation (it addresses only one component of mitochondrial dysfunction). Exercise, by contrast, activates every mitochondrial quality control pathway simultaneously — biogenesis, mitophagy, fusion-fission dynamics, protein turnover, and antioxidant enzyme upregulation — which is why no pharmacological intervention has matched exercise for mitochondrial health outcomes.

Safety, side effects, and tolerability

SS-31 has demonstrated a favorable safety profile across all published clinical trials, which is one of the genuinely positive findings from its clinical development program. The molecule appears to be well-tolerated even in seriously ill patient populations:

• Injection site reactions — The most common adverse event in subcutaneous dosing trials. Typically mild erythema, swelling, or discomfort at the injection site that resolves within hours. Reported in 15-30% of patients across trials
• Headache — Reported at slightly higher rates than placebo in some trials, though generally mild and transient
• No serious organ toxicity — Across Phase I through Phase III trials spanning hundreds of patients, no signal for hepatotoxicity, nephrotoxicity, cardiotoxicity, or hematological toxicity has emerged
• No immunogenicity signal — Despite being a synthetic peptide, SS-31 has not generated anti-drug antibodies at clinically significant rates in published trials
• Favorable cardiovascular safety — In heart failure trials, elamipretide showed no proarrhythmic effects, no blood pressure perturbations, and no adverse cardiac remodeling
• Theoretical concern — mitochondrial adaptation — Some researchers have raised the theoretical possibility that chronic SS-31 use could reduce the cell's endogenous mitochondrial quality control mechanisms (mitophagy, unfolded protein response) by reducing the ROS signals that trigger them. This has not been observed clinically but represents a biologically plausible concern for very long-term use

The safety data is arguably the strongest clinical finding for SS-31: it appears to be a remarkably well-tolerated molecule, even in populations with serious underlying disease. Whether it is effective is debated; whether it is safe is not, based on current data.

Access and availability in 2026

SS-31 is not approved for clinical use anywhere in the world as of April 2026. It is not available through standard medical channels, pharmacies, or compounding pharmacies with legitimate supply chains. The practical access landscape is limited to three channels:

• Clinical trials — Stealth BioTherapeutics continues development in select indications. Enrollment information is available through ClinicalTrials.gov. For patients with Barth syndrome, primary mitochondrial myopathy, or dry AMD, clinical trial participation represents the most legitimate access pathway
• Compassionate use / expanded access — In some jurisdictions, physicians can petition the FDA (or equivalent regulatory body) for individual-patient access to investigational drugs for serious or life-threatening conditions. This pathway exists but is bureaucratically demanding and requires a willing treating physician
• Research chemical suppliers — SS-31 is available from peptide synthesis companies as a research chemical. These products are explicitly labeled "not for human use" and carry significant concerns about purity, sterility, and accurate concentration. Anyone obtaining SS-31 through this route is self-experimenting with an unapproved research chemical from an unregulated source

Dosing from clinical trial protocols

The following dosing information is drawn exclusively from published clinical trials and is provided for informational context, not as medical guidance. SS-31 is not approved for any clinical use.

The consistent subcutaneous dose across multiple chronic-dosing trials was 40 mg daily, which produced measurable pharmacodynamic effects (improvements in mitochondrial function markers) with acceptable tolerability. This dose was selected through Phase I dose-ranging studies that established the pharmacokinetic profile and identified the therapeutic window.

Where does SS-31 development go from here?

Elamipretide's development path remains active but uncertain. Stealth BioTherapeutics faces the challenge that many rare disease biotech companies confront: the biology is sound, the unmet need is real, but the clinical trial framework required by the FDA is designed for common diseases with large available patient populations. Running a sufficiently powered, placebo-controlled trial in a disease that affects fewer than 1 in 300,000 births is logistically and financially formidable.

Several development paths remain open. The Barth syndrome indication could advance with an adequately powered controlled trial, potentially using natural history data as an external control arm. The AMD indication, with its larger patient population and clear unmet need (no approved therapy for dry AMD), offers a path to a broader market. And the aging biology data — while not currently the focus of regulatory filings — represents the most commercially attractive long-term opportunity if any indication achieves initial approval and establishes a safety track record.

The broader significance of SS-31 extends beyond the molecule itself. Regardless of whether elamipretide achieves FDA approval, SS-31 validated the concept of mitochondrial-targeted therapeutics and demonstrated that you can deliver a drug to the inner mitochondrial membrane in humans with a favorable safety profile. That proof of concept opens the door for next-generation mitochondrial therapeutics with potentially improved efficacy.

Frequently asked questions

Bottom line

SS-31 is one of the most scientifically elegant molecules in the longevity and mitochondrial medicine space. Its mechanism — targeting the mitochondrial inner membrane through cardiolipin binding — is genuinely novel and addresses a fundamental aspect of mitochondrial dysfunction that no supplement, antioxidant, or lifestyle intervention directly reaches. The preclinical data across multiple aging organ systems is consistently impressive.

The clinical reality is more humbling. Phase II and III trials have produced mixed results: signals of benefit in some endpoints and populations, but no clean primary endpoint win that has satisfied the FDA. The Barth syndrome rejection, while understandable on regulatory grounds, was a setback for patients with no approved alternatives. The heart failure trial's missed endpoint reflects the difficulty of translating mitochondrial-level improvements to organ-level outcomes in complex diseases.

For the general longevity-interested public, SS-31 is not a practical intervention in 2026. It is not available through legitimate medical channels, research chemical sources carry quality risks amplified by its synthetic complexity, and the human outcome data does not yet support the risk of self-experimentation. The molecule's scientific importance is undeniable — it proved that the mitochondrial inner membrane is a druggable target. Whether elamipretide itself becomes the drug that exploits that target, or whether it paves the way for a next-generation molecule that does, remains an open question.

In the meantime, the most effective mitochondrial health intervention remains the one with the largest and most consistent evidence base: regular exercise. It activates every mitochondrial quality control pathway simultaneously, it is free, and it works in humans — not just mice.

Keep reading

Peptides

NAD+: cellular energy, DNA repair, and the longevity molecule — 2026 evidence-based guide

Peptides

MOTS-C: the mitochondrial exercise-mimetic peptide — 2026 evidence-based guide

Peptides

Epitalon: the telomerase-activating longevity peptide — 2026 evidence-based guide